| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 22/11/2024 | 23:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 22/11/2024 | 22:03 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 12/11/2024 | 13:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 12/11/2024 | 13:08 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 12/11/2024 | 13:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 04/11/2024 | 13:30 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 18/10/2024 | 22:01 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 26/09/2024 | 12:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/09/2024 | 22:02 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/09/2024 | 04:34 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 11/09/2024 | 22:04 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 11/09/2024 | 22:01 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/09/2024 | 13:00 | GlobeNewswire Inc. | Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 27/08/2024 | 14:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 21/08/2024 | 14:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/08/2024 | 13:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/06/2024 | 13:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/05/2024 | 22:10 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/05/2024 | 14:01 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/05/2024 | 14:00 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 24/04/2024 | 03:36 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 23/04/2024 | 22:17 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 22/04/2024 | 13:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 28/03/2024 | 21:28 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 22/02/2024 | 14:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/02/2024 | 13:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/12/2023 | 14:00 | GlobeNewswire Inc. | Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 10/12/2023 | 18:05 | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 27/11/2023 | 22:15 | GlobeNewswire Inc. | Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 13/11/2023 | 22:05 | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |